10-Q: Fulgent Genetics Q2 2026 Results Show Revenue Growth Amidst Margin Pressure

Fulgent Genetics reported a 4% revenue increase for Q2 2026, driven by its anatomic pathology segment, but faced a significant gross margin decline due to system implementation issues and increased costs.

Summary

• Fulgent Genetics reported Q2 2026 revenue of $85.4 million, a 4% increase year-over-year, primarily driven by growth in its anatomic pathology services.
• For the six-month period ended June 30, 2026, revenue was $156.5 million, a 1% increase.
• Gross profit for the quarter decreased by 25% to $25.7 million, with gross margin falling to 30% from 42% in the prior year period.
• Operating expenses increased by 14% to $61.8 million, leading to an operating loss of $36.1 million for the quarter.
• The company incurred an impairment charge of $2.2 million on a customer relationship intangible asset.
• Net loss attributable to Fulgent for the quarter was $29.5 million, compared to $19.0 million in the prior year quarter.
• The company completed the acquisition of Bako Diagnostics and StrataDx for approximately $55.7 million, integrating them into its laboratory services segment.
• Cash, cash equivalents, and marketable securities stood at $551.5 million as of June 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to significant margin compression, widening losses, and ongoing operational challenges, despite modest revenue growth and strategic acquisitions.

Positives

• Revenue increased by 4% to $85.4 million in Q2 2026, driven by strong performance in anatomic pathology.
• Anatomic pathology revenue saw a significant increase of 33% year-over-year.
• The company completed the strategic acquisition of Bako Diagnostics and StrataDx, strengthening its laboratory services business.
• International revenue increased by 27% year-over-year for the quarter.
• The company has a strong liquidity position with $551.5 million in cash, cash equivalents, and marketable securities.

Negatives

• Gross profit decreased by 25% to $25.7 million in Q2 2026.
• Gross margin declined significantly to 30% from 42% in Q2 2025, attributed to billing system implementation issues and higher costs.
• Operating expenses increased by 14% to $61.8 million.
• The company reported an operating loss of $36.1 million for the quarter.
• Net loss attributable to Fulgent widened to $29.5 million in Q2 2026 from $19.0 million in Q2 2025.
• Precision diagnostics revenue decreased by 13% due to a major customer performing tests internally.
• An impairment charge of $2.2 million was recorded for a customer relationship intangible asset.

Risks

• The company faces ongoing challenges with its new billing and revenue cycle management system, leading to processing delays, collection backlogs, and potential uncollected amounts.
• A significant customer is transitioning testing services internally, leading to a decline in precision diagnostics revenue.
• The company relies on a limited number of suppliers for critical reagents and equipment, posing a risk of interruption if supply chains are disrupted.
• The company is subject to ongoing investigations by the U.S. Department of Justice (DOJ) and the U.S. Health Resources and Services Administration (HRSA) regarding billing practices and medically unnecessary testing.
• The company cannot predict the outcome or potential impact of ongoing government investigations and audits, which could materially and adversely affect its business.
• The therapeutic development segment faces risks associated with clinical trial progress, FDA approvals, and market acceptance of new drugs.
• The company's goodwill and intangible assets are subject to impairment assessments, with recent impairments noted.

Future Outlook

The company expects to continue investing in its laboratory services business and clinical trials for FID-007 and FID-022, anticipating increased operating expenses. Management expects gross margins to improve as remaining customizations for the new billing system are completed and integrated. An end of Phase 2 meeting for FID-007 with the FDA is scheduled before the end of August 2026, with a potential Phase 3 trial to commence in the first half of 2027.

Management Comments

• The Bako Acquisition closed late in the first quarter, and its full impact on consolidated results is expected in future periods.
• The company is actively seeking to address processing backlogs and collections delays related to its new billing and revenue cycle management system, but timely resolution is not guaranteed.
• The company expects revenues for its largest customer to continue to decline in 2026 as this customer increases its internal testing capabilities.
• The company expects research and development expenses to continue increasing as clinical trials progress for FID-007, FID-022, and other pre-clinical studies.

Industry Context

StockSavvy.ai notes that Fulgent Genetics' Q2 2026 results reflect broader industry trends of increasing operational complexity and the impact of system integrations on financial performance. The decline in precision diagnostics revenue due to customer insourcing is a common challenge in the lab services sector, while the therapeutic development segment's progress aligns with the industry's focus on oncology advancements.

Comparison to Industry Standards

• The gross margin of 30% for Q2 2026 is significantly below the typical gross margins for established diagnostic laboratories, which often range from 50% to 70%, indicating operational inefficiencies or pricing pressures.
• The increase in operating expenses as a percentage of revenue, coupled with the decline in gross margin, suggests a potential challenge in achieving economies of scale compared to larger, more integrated competitors like Quest Diagnostics or Labcorp, which generally maintain higher operating leverage.
• The therapeutic development segment's R&D spending, while increasing, needs to be benchmarked against industry peers in oncology drug development to assess its competitiveness and efficiency in advancing pipeline candidates.

Legal Proceedings

• The company is responding to a Civil Investigative Demand (CID) from the U.S. Department of Justice (DOJ) concerning allegations of medically unnecessary laboratory testing, improper billing, and violations of the Anti-Kickback Statute and Stark Law.
• The company is subject to an audit by the U.S. Health Resources and Services Administration (HRSA) regarding reimbursement for COVID-19 tests furnished to uninsured patients.
• The company received a CID from the DOJ regarding potential false claims submitted to the Uninsured Program.
• The company is a defendant in qui tam complaints filed under the False Claims Act, alleging false claims for reimbursement for COVID-19 tests.

Related Party Transactions

• Prior to April 25, 2025, Ming Hsieh (CEO) was a director and owner of ANP Technologies, Inc., with whom Fulgent had licensing and development service agreements.
• Ray Yin (President and CSO of Fulgent Pharma) is the Founder, President, and Chief Technology Officer of ANP Technologies, Inc.

Stakeholder Impact

• Shareholders may experience dilution if additional capital is raised through equity offerings.
• The company's ability to meet its financial obligations and pursue growth strategies could be impacted by ongoing legal proceedings and potential fines.
• Customers may be affected by potential disruptions or delays in service due to the billing system transition.
• Suppliers could face payment delays if the company's liquidity is impacted by the ongoing challenges.

Next Steps

• Complete remaining customizations for the billing and revenue cycle management system to improve collection rates and gross margins.
• Continue integration of Bako Diagnostics and StrataDx to strengthen the laboratory services business.
• Progress FID-007 through clinical trials, with an end of Phase 2 meeting with the FDA scheduled and a potential Phase 3 trial planned for early 2027.
• Focus on developing existing customers and increasing the customer base to reduce revenue concentration.
• Continue to monitor and respond to ongoing government investigations and audits.

Key Dates

Recommendation

While revenue showed modest growth and strategic acquisitions were made, the significant decline in gross margins, widening net loss, and ongoing operational and legal challenges warrant a cautious approach. The company's ability to resolve its billing system issues and navigate regulatory investigations will be critical for future performance.

Keywords

Genetics Testing, Laboratory Services, Anatomic Pathology, Precision Diagnostics, Therapeutic Development, Acquisition, Bako Diagnostics, Financial Results